These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22234814)

  • 1. [Neuroethics of pharmaceutical cognitive enhancement: the first ten years: current problems and practical guiding principles].
    Metzinger TK
    Fortschr Neurol Psychiatr; 2012 Jan; 80(1):36-43. PubMed ID: 22234814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethical issues in the use of cognitive enhancement.
    Darby R
    Pharos Alpha Omega Alpha Honor Med Soc; 2010; 73(2):16-22. PubMed ID: 20455376
    [No Abstract]   [Full Text] [Related]  

  • 3. Should one use medications in combination with cognitive training? If so, which ones?
    Yesavage J; Hoblyn J; Friedman L; Mumenthaler M; Schneider B; O'Hara R
    J Gerontol B Psychol Sci Soc Sci; 2007 Jun; 62 Spec No 1():11-8. PubMed ID: 17565161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroethical issues in cognitive enhancement.
    Sahakian BJ; Morein-Zamir S
    J Psychopharmacol; 2011 Feb; 25(2):197-204. PubMed ID: 20212064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive enhancement: promises and perils.
    Hyman SE
    Neuron; 2011 Feb; 69(4):595-8. PubMed ID: 21338872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of the Dementia Rating Scale-2 and cognitive enhancers in the diagnosis and treatment of cognitive disorders and dementia.
    Caston JC; Diehl LA; Hedgepath AW
    J S C Med Assoc; 2004 Feb; 100(2):32-8. PubMed ID: 15040232
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2010 Mar; 8(91):19-24. PubMed ID: 20179667
    [No Abstract]   [Full Text] [Related]  

  • 8. In search of optimal psychoactivation: stimulants as cognitive performance enhancers.
    Rozenek EB; Górska M; Wilczyńska K; Waszkiewicz N
    Arh Hig Rada Toksikol; 2019 Sep; 70(3):150-159. PubMed ID: 32597132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocognitive enhancement: what can we do and what should we do?
    Farah MJ; Illes J; Cook-Deegan R; Gardner H; Kandel E; King P; Parens E; Sahakian B; Wolpe PR
    Nat Rev Neurosci; 2004 May; 5(5):421-5. PubMed ID: 15100724
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of cognitive impairment in schizophrenia.
    Goff DC; Hill M; Barch D
    Pharmacol Biochem Behav; 2011 Aug; 99(2):245-53. PubMed ID: 21115035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drug development for cognitive enhancement in mental health: challenges and opportunities.
    Insel T; Krystal J; Ehlers M
    Neuropharmacology; 2013 Jan; 64():2-7. PubMed ID: 23145450
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuropharmacological aspects of cognitive neurorehabilitation in epilepsy.
    Mula M; Trimble MR
    Behav Neurol; 2006; 17(1):69-75. PubMed ID: 16720961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Cognitive Enhancement in Healthy Individuals: A Compensation for Cognitive Deficits or a Question of Personality?
    Maier LJ; Wunderli MD; Vonmoos M; Römmelt AT; Baumgartner MR; Seifritz E; Schaub MP; Quednow BB
    PLoS One; 2015; 10(6):e0129805. PubMed ID: 26107846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive Enhancement: Treating or Cheating?
    Whetstine LM
    Semin Pediatr Neurol; 2015 Sep; 22(3):172-6. PubMed ID: 26358427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nootropic drugs: definition, classification, mechanism of action, clinical effectiveness, substances].
    Kuhlmey J
    Z Arztl Fortbild (Jena); 1994 Sep; 88(9):697-701. PubMed ID: 7975756
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroenhancement: wisdom of the masses or "false phronesis"?
    Larriviere D; Williams MA
    Clin Pharmacol Ther; 2010 Oct; 88(4):459-61. PubMed ID: 20856244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive issues in Parkinson's disease.
    Elmer L
    Neurol Clin; 2004 Oct; 22(3 Suppl):S91-S106. PubMed ID: 15501368
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy, safety, and ethics of cosmetic neurology far from settled.
    Flower K; Li L; Chen CY; Baggott MJ; Galloway GP; Mendelson J
    Clin Pharmacol Ther; 2010 Oct; 88(4):461-3. PubMed ID: 20856245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for cognitive loss and dementia.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):155-161. PubMed ID: 28922342
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.